IDYA — IDEAYA Biosciences, Inc.
$32.89-3.15%
Last close: · regular session
Last 60 sessions
IDYA closed at $32.89 (-3.15%) on Oct 29, 2026. Active automatic shelf (S-3ASR, May 2026); dilution risk: medium. Float: 87.1M shares. Latest SEC filing: SCHEDULE 13G on Aug 14, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for IDYA in the TickerWise workspace.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 131
- Website: https://www.ideayabio.com
Latest SEC filings for IDYA
Latest IDYA news
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Read article
- IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma Read article
- IDEAYA resumed at Buy at Stifel on combo treatment for uveal melanoma Read article
- IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in Stock Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.